

THE LANCET

Infectious Diseases

Supplementary appendix

This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Supplement to: Perico N, Cortinovis M, Suter F, Remuzzi G. Home as the new frontier for the treatment of COVID-19: the case for anti-inflammatory agents. *Lancet Infect Dis* 2022; published online Aug 25. [https://doi.org/10.1016/S1473-3099\(22\)00449-2](https://doi.org/10.1016/S1473-3099(22)00449-2).

SUPPLEMENTARY MATERIAL

Table S1. Studies that examined non-steroidal anti-inflammatory drugs for COVID-19 treatment in the general population.

Study	Exposure	Timing of exposure	Patient population	Age (years)	Male (%)	Primary Outcome	Exposure group	Control group	Between group difference, P value
Abu Esba et al. 2021	Ibuprofen	Acute use during infection	503 COVID-19 patients	Ibuprofen users, 35 [27 to 44]; non-NSAID users, 36 [27 to 49]	59.2%	30-day mortality	1/40 (2.5%)	11/357 (3.1%)	Adjusted HR 0.63 (95% CI 0.07 to 5.44), P=0.676
Drake et al. 2021	NSAIDs	Within two weeks before hospital admission	72,179 patients hospitalized with confirmed or highly suspected SARS-CoV-2 infection	NSAID users, 70.1 (18.7); non-NSAID users, 70.2 (18.4)	56.2%	In-hospital mortality	1,273/4205 (30.3%)	1,324/4,205 (31.5%)	Matched OR 0.95 (95% CI 0.84 to 1.07), P=0.35
Jeong et al. 2021	NSAIDs	Within 7 days before hospitalization	1,824 patients hospitalized with COVID-19	NSAID users, 54.1 (17.6); non-NSAID users, 47.8 (19.1)	41.1%	Combination of in-hospital death, ICU admission, mechanical ventilation use, and sepsis	22/354 (6.2%)	52/1,470 (3.5%)	IPTW OR 1.54 (95% CI 1.13 to 2.11)
Kragholm et al. 2020	Ibuprofen	Prescription claims from 1 January to 30 April 2020, and before COVID-19 diagnosis	4,002 COVID-19 patients	Ibuprofen prescription, 58 [46 to 68]; no ibuprofen prescription, 57 [45 to 73]	47.3%	Combination of severe COVID-19, ICU admission, or death at 30 day	42/264 (15.9%)	646/3,738 (17.3%)	Standardized average RR 0.96 (95% CI 0.72 to 1.23)
Lund et al. 2020	NSAIDs	Prescription up to 30 days before a positive SARS-CoV-2 test	9,236 COVID-19 patients	NSAID users, 55 [43 to 64]; non-NSAID users, 49 [35 to 63]	42.1%	30-day mortality	14/224	55/896	RR 1.02 (95% CI 0.57 to 1.82), P=0.95
Rinott et al. 2020	Ibuprofen	From a week before diagnosis of COVID-19	403 COVID-19 patients	45 [25 to 62]	54.6%	Mortality	3/87 (3.4%)	9/316 (2.8%)	Proportion difference 0.6%, 95% CI -4.3% to 5.5%, P>0.95
						Need for respiratory support	9/87 (10.3%)	35/316 (11.1%)	Proportion difference -0.8%, 95% CI -8.7% to 7.3%, P>0.95
Wong et al. 2021	NSAIDs	Prescription within the previous 4 months	2,463,707 people prescribed NSAIDs in the past 3 years	Current NSAID users, 53 [42 to 64]; non-NSAID users, 49 [36 to 60]	42.7%	COVID-19-related mortality	220/536,423	612/1,927,284	Adjusted HR 0.96 (95% CI 0.80 to 1.14)

Data are mean (SD) or median [interquartile range]. CI, confidence interval; HR, hazard ratio; ICU, intensive care unit; IPTW, inverse probability of treatment weighted; NSAID, non-steroidal anti-inflammatory drugs; OR, odds ratio; RR, risk ratio.

Figure S1. Home as a new frontier for COVID-19.

HOME WILL BE NEW FRONTIER



*Use the never ending capacity
of home bed*

This is the future

Ron Sabar - Sabar Health, Israel

Naim Mahroum - Sheba Medical Center, Israel